CN105007940B - 与癌症治疗相关的方法和组合物 - Google Patents

与癌症治疗相关的方法和组合物 Download PDF

Info

Publication number
CN105007940B
CN105007940B CN201380073538.9A CN201380073538A CN105007940B CN 105007940 B CN105007940 B CN 105007940B CN 201380073538 A CN201380073538 A CN 201380073538A CN 105007940 B CN105007940 B CN 105007940B
Authority
CN
China
Prior art keywords
isc
cetuximab
cancer
prodrugs
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380073538.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105007940A (zh
Inventor
J·E·艾伦
W·S·艾尔-戴利
A·K·沙玛
S·G·阿敏
R·厄比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of CN105007940A publication Critical patent/CN105007940A/zh
Application granted granted Critical
Publication of CN105007940B publication Critical patent/CN105007940B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380073538.9A 2012-12-20 2013-12-20 与癌症治疗相关的方法和组合物 Expired - Fee Related CN105007940B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740126P 2012-12-20 2012-12-20
US61/740,126 2012-12-20
PCT/US2013/076869 WO2014100565A1 (en) 2012-12-20 2013-12-20 Methods and compositions relating to treatment of cancer

Publications (2)

Publication Number Publication Date
CN105007940A CN105007940A (zh) 2015-10-28
CN105007940B true CN105007940B (zh) 2017-08-25

Family

ID=49950064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380073538.9A Expired - Fee Related CN105007940B (zh) 2012-12-20 2013-12-20 与癌症治疗相关的方法和组合物

Country Status (10)

Country Link
US (1) US20150328310A1 (enExample)
EP (1) EP2934583A1 (enExample)
JP (1) JP2016503063A (enExample)
KR (1) KR20150099588A (enExample)
CN (1) CN105007940B (enExample)
AU (1) AU2013361164A1 (enExample)
CA (1) CA2894547A1 (enExample)
RU (1) RU2015129366A (enExample)
SG (1) SG11201504779YA (enExample)
WO (1) WO2014100565A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005849A1 (en) * 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
BR112022014149A2 (pt) 2020-01-22 2022-09-27 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidina-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrila

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
WO2008128189A1 (en) * 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and Anticancer Activity Comparison of Phenylalkyl Isoselenocyanates with Corresponding Naturally Occurring and Synthetic Isothiocyanates;Arun K. Sharma et al.;《journal of medicinal chemistry》;20081225;第25卷(第24期);第7822第2段至7824页第1段，图2 *
近年来前体药物的进展概况;张奕华等;《药学进展》;19850131(第1期);第1-13页 *

Also Published As

Publication number Publication date
WO2014100565A1 (en) 2014-06-26
AU2013361164A1 (en) 2015-07-02
CN105007940A (zh) 2015-10-28
CA2894547A1 (en) 2014-06-26
US20150328310A1 (en) 2015-11-19
KR20150099588A (ko) 2015-08-31
EP2934583A1 (en) 2015-10-28
SG11201504779YA (en) 2015-07-30
RU2015129366A (ru) 2017-01-25
JP2016503063A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
JP7600286B2 (ja) 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
JP2023060196A5 (enExample)
KR101765575B1 (ko) 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 암 줄기세포의 성장 억제용 약학적 조성물
TW201138819A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
TWI551288B (zh) Antimicrobial activity enhancer for chemotherapeutic agents
KR20200026969A (ko) 치료제의 비경구 투여를 위한 조성물
CN105007940B (zh) 与癌症治疗相关的方法和组合物
CN103536925B (zh) 强心苷化合物在非小细胞肺癌治疗中的应用
Thomas et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer: GFPC 99-01 study (Groupe français de pneumo-cancérologie)
US20150258139A1 (en) Methods for treatment of cancer using lipoplatin
HK40033622A (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
UA97504C2 (uk) Спосіб зниження ризику виникнення або відстрочення виникнення раку у суб'єкта із застосуванням анти-vegf антитіла

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170825

Termination date: 20181220